Population
Cells infected with Coxsackievirus A9 (CVA9)
Design
Preclinical
Authors
Loading...
Identifies MVB-dependent CVA9 entry as a potential target; leaves open whether PLC or Rac1 inhibition yields clinical antivirals.
CVA9 uses a nonclathrin, nonacidic pathway involving neutral multivesicular bodies for cellular infection.
Huttunen et al. (2014) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: